Welcome

Thank you for stopping by and welcome to my blog! Your presence here means a lot to me!

Your feedback holds immense value. Whether it's praise, constructive criticism, or suggestions, I genuinely treasure your input. While receiving criticism is not always easy, I do believe that honest feedback, presented in a positive manner, serves as a catalyst for growth and improvement. Your insights will help shape the direction of this blog, and I'd love to hear from you!

Don't Compromise Control Groups

Randomized, double-blind, controlled trials (RCTs) are widely considered the gold standard for modern intervention-based clinical...

May 242 min read

Understanding FDA Recommendations for Covariate Adjustment in Randomized Clinical Trials

In May 2023, the US Food and Drug Administration (FDA) issued final guidance on adjusting for covariates in randomized clinical trials...

Aug 25, 20246 min read

A Cautionary Note on Correlation Analysis Using Post-Treatment Predictors

When a clinical trial demonstrates positive efficacy results, there is often interest in conducting various post-hoc analyses, including...

Aug 23, 20242 min read

The Pathological Distribution Behind the Number Needed to Treat (NNT)

A recent LinkedIn post by a fellow statistician caught my attention. The author touted the appealing concept of NNT, which is widely...

Jun 9, 20243 min read

Be a free thinker and don't accept everything you hear as truth. Be critical and evaluate what you believe in.

― Aristotle

Hi, I’m Andrew

A statistician passionate about sharing thoughts and ideas on statistical issues in drug development. I believe that we are trained for critical thinking rather than merely following, and we bear a unique responsibility in a world full of randomness and uncertainty. This belief is what drives this blog. I'm committed to delivering content that's not only interesting but also thought-provoking and intellectually engaging.